Fig. 5: DF-003 decreases astrocyte activation in the retinas of ROSAH model mice.
From: Discovery of a selective alpha-kinase 1 inhibitor for the rare genetic disease ROSAH syndrome
Female hALPK1-KI and hALPK1[T237M]-KI mice were treated orally with DF-003 once per day for 10 days at the indicated doses (n = 8 animals for each group). a After dosing was complete, retinal cross-sections were collected and stained with anti-GFAP antibody to label activated astrocytes via immunohistochemistry. The signal was mainly observed in the nerve fiber layer of the retina. b The percentage of the retinal length of the nerve fiber layer that was positive for GFAP-labeled astrocyte fibers was quantified. Data represent means ± SEM for each genetic and treatment group, with each dot representing the measurement of one section from one animal. In the first 5 groups, there were 1–2 animals excluded from the analyses due to unsuccessful processing of retina samples, which affected the integrity of GFAP staining in the nerve fiber layer. Statistical comparisons between vehicle groups of the two genotypes were made using two-tailed unpaired Student’s t-tests: F = 1.646, t = 8.139, df = 11, r2 = 0.8576, 95% confidence interval (CI) 19.62 to 34.16, p = 0.0000055; and comparisons between DF-003 dosed groups and the vehicle group within the same genotype were made with one-way ANOVAs followed by Sidak’s post hoc tests: t = 3.55, df = 19, 95% CI 4.18 to 22.23, p = 0.0043 between vehicle and 3 mg/kg group; t = 3.87, df = 19, 95% CI 5.21 to 22.69, p = 0.002 between vehicle and 5 mg/kg group.
